Ipca Laboratories Limited (BOM: 524494)
India
· Delayed Price · Currency is INR | Market Cap | 392.51B |
| Revenue (ttm) | 85.34B |
| Net Income (ttm) | 6.61B |
| Shares Out | n/a |
| EPS (ttm) | 26.05 |
| PE Ratio | 59.36 |
| Forward PE | n/a |
| Dividend | 4.00 (0.26%) |
| Ex-Dividend Date | Nov 27, 2024 |
| Volume | 14,560 |
| Average Volume | 13,985 |
| Open | 1,526.70 |
| Previous Close | 1,543.70 |
| Day's Range | 1,501.75 - 1,555.00 |
| 52-Week Range | 1,058.70 - 1,757.65 |
| Beta | n/a |
| RSI | 39.29 |
| Earnings Date | Feb 13, 2025 |
About Ipca Laboratories
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabe... [Read more]
Financial Performance
In 2023, Ipca Laboratories's revenue was 77.06 billion, an increase of 23.33% compared to the previous year's 62.48 billion. Earnings were 5.47 billion, an increase of 16.13%.
Financial StatementsNews
Stock Market Update, January 2: Lupin, Eicher Motors, IPCA Laboratories, Mahindra & Mahindra and more hit 52-week highs today
The Indian equity market witnessed a robust performance on January 2, 2025, with key indices surging significantly. The Nifty 50 index gained 445.75 points, or 1.88 percent, to close at 24,188.65, whi...
Motilal Oswal maintains ‘buy’ rating on Ipca Labs, expects 21% upside potential
Motilal Oswal Securities Limited (MOSL) has reiterated its “buy” rating on Ipca Laboratories, setting a target price of ₹1980. This implies an upside potential of 21% from the current market price of ...
IPCA Laboratories shares rise over 2% following promoter’s Rs 600 crore stake sale
Shares of Ipca Laboratories Ltd. gained 2.04%, trading at ₹1,544 on December 19 after a key promoter offloaded a significant stake. The pharmaceutical giant saw increased market activity after the dev...
Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline
The pharma sector showed a mixed trend during intraday trading as of 11:25 AM, with select stocks gaining while others faced selling pressure. Key Performances: Gaining Stocks: IPCA Laboratories: Up 0...
IPCA Laboratories revises record date to 27th November for Rs. 2 interim dividend
The interim dividend of Rs. 2/- per share (200%) was declared at a meeting of the Board of Directors on Thursday, 14th November 2024. The revised record date will determine the entitlement of members ...
IPCA Laboratories shares surge 2% on strong Q2 results
IPCA Laboratories Ltd. saw a 2% rise in its stock price following impressive Q2 results for the September quarter. The company reported a 58% year-on-year increase in net profit, reaching ₹229.48 cror...
IPCA Laboratories Q2 FY25 Results: Revenue up 15.8% YoY to Rs 2,354.90 crore, Net Profit up 57.9% YoY to 229.48 crore
IPCA Laboratories has reported its financial results for the second quarter of FY25, showing growth in revenue and profitability compared to the same period last year. Key Financial Highlights for Q2 ...
Ipca Laboratories Q2 results: Check share price ahead of Q2 results
Ipca Laboratories shares are currently trading at ₹1,520.00, up by 1.01% as the company prepares to announce its second-quarter earnings. With a total market cap of ₹38,512.30 crore, the stock’s 52-we...
IPCA Laboratories shares decline over 3% ahead of Q2 earnings report
Shares of IPCA Laboratories Ltd. fell more than 3% on the NSE as investors brace for the company’s Q2 FY25 earnings results. As of 11:14 AM, the stock was trading 2.88% lower at ₹1,514.60. Market expe...